QQ客服 官方微博 反馈留言

	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study
	Langleben, David; Galie, Nazzareno; He, Jianguo; Huang, Yigao; Humbert, Marc; Keogh, Anne; Rubin, Lewis J.; Zhou, Daxin; Curram, John; Davie, Neil
刊名	JOURNAL OF HEART AND LUNG TRANSPLANTATION
	2015
卷号	34期号:3
关键词	pulmonary arterial hypertension riociguat soluble guanylate cyclase stimulator treatment response responder threshold criteria
ISSN号	1053-2498
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4871546
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Langleben, David,Galie, Nazzareno,He, Jianguo,et al. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION,2015,34(3).
APA	Langleben, David.,Galie, Nazzareno.,He, Jianguo.,Huang, Yigao.,Humbert, Marc.,...&Ghofrani, Hossein-Ardeschir.(2015).Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study.JOURNAL OF HEART AND LUNG TRANSPLANTATION,34(3).
MLA	Langleben, David,et al."Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study".JOURNAL OF HEART AND LUNG TRANSPLANTATION 34.3(2015).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。